Latest Everfront Biotech News & Updates

See the latest news and media coverage for EFB. We track all announcements, press releases, and industry mentions in real time, all in one place.

Everfront Biotech (EFB)

Orphan drug developer for lethal diseases

Latest news about Everfront Biotech (EFB)

17 November 2025 EFB

Everfront Biotech presents updated Cerebraca Wafer results at SNO 2025

The e-poster covers Phase I/IIa trial data for Recurrent Glioblastoma treatment and Phase IIb/III plans. No drug-related adverse effects reported.
14 October 2025 EFB

Everfront Biotech presents Cerebraca® Wafer trial results at CNS meeting

Phase I/IIa trial shows 15.7 months median survival, no serious adverse events. Plans global Phase IIb trial launch late 2025.
28 November 2024 EFB

Everfront Biotech unveils Cerebraca® Wafer trial results

Dr. Jen-Wei Liu presents Phase I/IIa outcomes at 2024 Taiwan Healthcare+ Expo, showing 26.2 months median survival and no direct side effects.
28 June 2024 EFB

EFB showcases Cerebraca® Wafer at BIO 2024

The Taiwan biotech delegation highlights innovations including EFB's glioblastoma treatment with superior survival rates in trials. Event fosters partnerships and collaborations.

23 June 2025 Investing.com

Everfront Biotech Files for Proposed IPO

Everfront Biotech (EFB) has filed for a proposed IPO. The company describes itself as: "We are a clinical stage biopharmaceutical company dedicated to the discovery...

Never miss news about EFB

Track EFB and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.